Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
Completed · Phase 3
Conditions studied: Prostatic Neoplasms
In brief
The overall goal of this proposal is to determine the effectiveness and safety of once weekly alendronate (Fosamax) in the prevention and treatment of osteoporosis in men with prostate cancer on androgen deprivation therapy and to evaluate maintenance of bone mass following termination of therapy after one year.
Key facts
- Study ID
- NCT00177619
- Run by
- University of Pittsburgh
- People needed
- 120
- Starts
- 2002-05-01
- Expected to finish
- 2005-12-01
- Last updated by the study team
- 2014-02-11
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Men age 18 and older with stage Do prostate cancer (as defined by asymptomatic disease, rising PSA, and negative bone scans) following attempted curative surgery and/or radiation
- Androgen deprivation therapy (gonadotropin releasing hormone agonists, lutenizing hormone releasing hormone agonists, testosterone antagonists, orchiectomy) for at least 6 months for treatment of prostate cancer
You may not qualify if…
- History of any illness known to affect bone and mineral metabolism (renal failure, hepatic failure, Paget's disease, osteogenesis imperfecta, osteomalacia)
- Non-prostate cancer diagnosed within last 5 years (treated superficial basal and squamous cell carcinoma excepted)
- Hyperparathyroidism
- Malabsorption
- Treatment with medications known to affect bone metabolism (chronic high-dose corticosteroid therapy for at least 6 months, thyroid hormone with TSH <0.1 micrograms, antiseizure medications)
- Active peptic ulcer
- Inability to sit upright or stand for at least 30 minutes
- Kidney stones in the past 5 years
- 24-hour urine calcium value >400 mg/24 hours
- Esophageal stricture or achalasia
- Hyperthyroidism
- Evidence of chronic liver disease (including alcoholism)
- Treatment within past year for osteoporosis (calcitonin, fluoride, bisphosphonates)
- History of atraumatic fractures, previous fracture due to a fall from standing height or lesser trauma, or clinical osteoporosis
- Metastatic prostate cancer
- Inability to provide written informed consent
Where it is running
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.